Prevalence of Methamphetamine Acute Coronary Syndrome Is 14.8 Percent

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on April 29, 2026.

via HealthDay

WEDNESDAY, April 29, 2026 -- The prevalence of methamphetamine-associated acute coronary syndrome (ACS) is 14.8 percent, and patients are generally younger men, according to a study published online April 29 in the Journal of the American Heart Association.

Susan X. Zhao, M.D., from Santa Clara Valley Medical Center in San Jose, California, and colleagues conducted a retrospective cohort study involving 1,309 patients aged 18 to 65 years who presented with ACS and underwent coronary angiography from 2012 to 2022 to examine the prevalence and outcomes of methamphetamine-associated ACS.

The researchers identified 194 patients with methamphetamine-associated ACS, for a prevalence of 14.8 percent. Compared with the 1,115 patients with ACS without methamphetamine use, patients with methamphetamine-associated ACS were generally younger men (median age, 52 versus 57 years). Patients with methamphetamine-associated ACS more often had nonobstructive coronary diseases (24.2 versus 10.6 percent). These patients also experienced significantly lower survival, despite being younger and having a lower burden of traditional risk factors; this pattern persisted after adjustment for confounders. The strongest independent predictor of all-cause mortality was methamphetamine use in multivariable Cox regression, with an adjusted hazard ratio of 2.08.

"We want to raise awareness that acute coronary syndrome and meth use affect different groups of people, such as young to middle-aged men without traditional risk factors," Zhao said in a statement. "These groups have different risk factors and health issues, and they also can have a higher chance of dying from them."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords